All In Biotech

Free tool

FAERS Monitor: Symbravo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215431 or its brand name (Symbravo, Meloxicam, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.

Reports

36

Serious

3

8% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness5
  • drug ineffective5
  • fatigue3
  • feeling abnormal3
  • headache3
  • nausea3
  • palpitations3
  • asthenia2
  • burning sensation2
  • flushing2
  • paraesthesia2
  • tachycardia2
  • abdominal pain1
  • abdominal pain upper1
  • amnesia1

Reports by year received

View as table
YearReports
202512
202624

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,123 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
burning sensation216.74.316
palpitationsSignal315.05.127
tachycardia213.23.412
flushing211.53.010
amnesia19.01.31
paraesthesia27.41.96
feeling abnormalSignal37.32.511
dizzinessSignal55.92.616
asthenia23.10.81
abdominal pain upper12.80.40
headache32.80.92
abdominal pain12.50.40
fatigue32.30.81
drug ineffective52.21.02
nausea32.20.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.